Savara Inc SVRA Stock Price Today, Quote & News

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization.

• High institutional ownership can be a signal of strong market trust in this company.
• For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more.
• The industry with the worst average Zacks Rank would place in the bottom 1%.
• Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
• The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. The scores are based on the trading styles of Value, Growth, and Momentum.

It can also be https://1investing.in/ by dividing the company’s Market Cap by the Net Profit. Wainwright maintained a Buy rating on Savara (SVRA – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $1.13, close to its 52-week … Represents the company’s profit divided by the outstanding shares of its common stock. Savara Inc. is a clinical-stage pharmaceutical company.

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction. Long term, RSI ready to spring Savara Inc. operates as an orphan lung disease company. Savara Inc. operates as an orphan lung disease company. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

Charts

There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Savara’s stock was trading at $1.55 on January 1st, 2023. Since then, SVRA shares have increased by 21.3% and is now trading at $1.88. According to analysts’ consensus price target of $2.50, Savara has a forecasted upside of 33.0% from its current price of $1.88.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools. Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more. Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat’s FREE daily newsletter.

Inflation & Prices

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

The clinical-the money multiplier and the expansion of the focuses on therapies to treat rare respiratory diseases. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

Savara Inc 52 week low is $1.06 as of May 01, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Savara Inc 52 week high is $2.85 as of May 01, 2023. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyondspring (BYSI – Research Report) and Savara (SVRA – Research Report) with bullish sentiments. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Latest On Savara Inc

For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more. Provides a general description of the business conducted by this company. Oversold gem for a discounted price Finding nice support on 200 day most of my analysis focuses on this blue line because it acts as Great support or great resistance. Finding nice support on 200 day most of my analysis focuses on this blue line because it acts as Great support or great resistance. There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.

The P/E ratio of Savara is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Savara has a short interest ratio (“days to cover”) of 4.3. Savara has only been the subject of 2 research reports in the past 90 days. Right-click on the chart to open the Interactive Chart menu.

Markets

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara (SVRA – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.71.According to TipRanks, Fein is an analy… Wainwright reiterated a Buy rating on Savara (SVRA – Research Report), with a price target of $3.00.

After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. 2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Savara in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” SVRA shares. View SVRA analyst ratings or view top-rated stocks.

It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET.

The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

The company’s shares closed last Friday at $1.17.Fein covers the Health… Shares of Savara Inc. tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S. Food and Drug Administration found data provided in a briefing package on its Molgradex program were not … According to 2 analysts, the average rating for SVRA stock is “Buy.” The 12-month stock price forecast is $2.5, which is an increase of 32.98% from the latest price. A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares.

Overview

In the past three months, Savara insiders have not sold or bought any company stock. MarketBeat has tracked 1 news article for Savara this week, compared to 1 article on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Other market data may be delayed by 15 minutes or more. Savara , LGL Group and Harte Hanks have been selected as the breakout stocks for today. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.

Live educational sessions using site features to explore today’s markets. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Shares in Savara Inc. , which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target.

The firm’s lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment… At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

News flow

You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of SVRA stock can currently be purchased for approximately $1.88. 75.51% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

• The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
• Savara Inc. operates as an orphan lung disease company.
• The monthly returns are then compounded to arrive at the annual return.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.